Open | $2.361 |
Close | $2.390 |
Volume / Avg. | 7.641K / 18.678K |
Day Range | 2.361 - 2.603 |
52 Wk Range | 1.810 - 3.570 |
Market Cap | $193.212M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 41 |
Short Interest | % |
Days to Cover | 10.51 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Innate Pharma (NASDAQ: IPHA) through any online brokerage.
Other companies in Innate Pharma’s space includes: Graphite Bio (NASDAQ:GRPH), FibroGen (NASDAQ:FGEN), GlycoMimetics (NASDAQ:GLYC), Agenus (NASDAQ:AGEN) and Genelux (NASDAQ:GNLX).
The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.50 expecting IPHA to rise to within 12 months (a possible 377.18% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Innate Pharma (NASDAQ: IPHA) is $2.41 last updated March 18, 2024 at 7:00 AM EDT.
There are no upcoming dividends for Innate Pharma.
Innate Pharma’s FY earnings are confirmed for Thursday, March 21, 2024.
There is no upcoming split for Innate Pharma.
Innate Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.